Scientists probe why standard drug doses may fail obese patients
NCT ID NCT05589688
Summary
This study aims to understand how body composition, specifically lean muscle mass, affects how the antiviral drug acyclovir is processed and eliminated by the kidneys in people with different body weights. Researchers will measure drug levels in the blood and urine of 20 healthy volunteers across a range of body mass indexes (BMI). The goal is to gather data to help doctors prescribe more accurate and effective doses for obese patients in the future.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OBESITY are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Toulouse Hospital
RECRUITINGToulouse, France
Contact
Conditions
Explore the condition pages connected to this study.